Sample Size Based on Pharmacodynamic endpoints [Power / Sample Size]

posted by nobody – 2019-04-05 08:37 (769 d 21:57 ago) – Posting: # 20124
Views: 2,559

» The fact that it is also a royal waste of money is of course only secondary.

Full-blown development mode. Accept it. Tell the sponsor you can't do the trial, if you are not qualified for PD-endpoint testing.

Kindest regards, nobody

Complete thread:

 Admin contact
21,460 posts in 4,486 threads, 1,511 registered users;
online 9 (0 registered, 9 guests [including 6 identified bots]).
Forum time: Friday 06:34 CEST (Europe/Vienna)

Art is “I”; science is “we”.    Claude Bernard

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz